GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NGM Biopharmaceuticals Inc (NAS:NGM) » Definitions » Cyclically Adjusted PB Ratio

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Cyclically Adjusted PB Ratio : (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is NGM Biopharmaceuticals Cyclically Adjusted PB Ratio?

NGM Biopharmaceuticals does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


NGM Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NGM Biopharmaceuticals Cyclically Adjusted PB Ratio Chart

NGM Biopharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial - - - - -

NGM Biopharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.



NGM Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NGM Biopharmaceuticals does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


NGM Biopharmaceuticals  (NAS:NGM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NGM Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NGM Biopharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NGM Biopharmaceuticals (NGM Biopharmaceuticals) Business Description

Traded in Other Exchanges
Address
333 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include NGM282 (aldafermin), NGM313 (MK-3655), NGM120, NGM120, NGM621, and NGM395, all these are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Executives
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Jean-frederic Viret officer: Chief Financial Officer ANESIVA, INC., 650 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Irene Perlich officer: Principal Accounting Officer C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jin-long Chen director, officer: Chief Scientific Officer 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Iv-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iv, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tcg Iv Gp, Llc 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
David J Woodhouse director, officer: CEO and acting CFO 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080

NGM Biopharmaceuticals (NGM Biopharmaceuticals) Headlines

From GuruFocus

NGM Bio to Participate in Upcoming Investor Conferences

By sperokesalga sperokesalga 05-25-2023

NGM Bio to Participate in Upcoming Investor Conferences

By GuruFocusNews GuruFocusNews 07-02-2022

NGM Bio to Participate in Upcoming Investor Conferences

By PurpleRose PurpleRose 07-12-2022